A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive Function Decline
Launched by CHANG GUNG MEMORIAL HOSPITAL · Jul 20, 2015
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to whole brain radiotherapy (WBRT) that aims to protect an important part of the brain called the hippocampus, which is crucial for memory. The researchers want to see if this “hippocampal sparing” method can help patients with brain metastases (cancer that has spread to the brain) experience less decline in their cognitive functions, such as memory and thinking skills, after treatment. The trial is currently recruiting participants who are between the ages of 65 and 80, have certain types of cancer, and are in good overall health. Specifically, eligible patients should have a maximum of three brain metastases that are not too large.
If you decide to participate in the trial, you can expect to receive either the standard WBRT treatment or the new method that spares the hippocampus. Throughout the study, researchers will carefully assess any changes in your cognitive abilities over time. This trial is important because it could lead to better treatment options that help preserve memory and cognitive function for patients undergoing radiation therapy for brain cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with pathologically-confirmed non-hematopoietic malignancy who are referred for therapeutic or prophylactic WBRT
- • Good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky Score (KPS) at least 70 %
- • The number and extent of brain metastatic lesions should be no more than three metastatic foci with a greatest diameter no more than 4 cm
- Exclusion Criteria:
- • Patients with MRI-identified metastasis within 5 mm perihippocampally
- • Clinical suspicion of leptomeningeal spreading
- • History of prior radiotherapy including stereotactic radiosurgery delivered to brain/head region for any reasons
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taoyuan, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials